HUM · Humana Inc.

Current Thesis

Humana's Medicare Advantage margin reset supports a continuation thesis that succeeds on an adjusted daily close above $409.42 before a daily close below $383. The 2026-09-09 adjusted close of $400.02 leaves that outcome unresolved. Management's underlying objective remains a pre-tax Medicare Advantage (MA) margin of at least 3% in 2028, reiterated on 2026-07-29; this is a company forecast, not a measured recovery. July earnings call.

The latest analyst record extends attention without raising the cited objective: Stock Analysis lists Bernstein maintaining its $425 analyst target on 2026-09-09. Analyst record.

The narrative is maturing — the 2026-09-01 earnings reaffirmation and Bernstein's unchanged 2026-09-09 target extend the existing recovery story. This is an inference about the information cycle; a raised company outlook accompanied by an adjusted daily close above $409.42 would contradict it. September filing, analyst record.

Bullish and bearish views on Humana Inc.

The model's bull view on Humana Inc. (HUM), in brief: Quarterly costs matched expectations. Humana reported a second-quarter insurance benefit ratio of 91.2% on 2026-07-29, consistent with management's expectation of slightly above 91%. This measures benefit expense relative to premium revenue; one quarter cannot establish a… The bear view: Annual medical pressure remains unresolved. Both cases follow in full.

Bull Case

• Quarterly costs matched expectations. Humana reported a second-quarter insurance benefit ratio of 91.2% on 2026-07-29, consistent with management's expectation of slightly above 91%. This measures benefit expense relative to premium revenue; one quarter cannot establish a durable margin recovery. Quarterly release.
• The earnings floor remains intact. The 2026-09-01 filing reaffirmed fiscal 2026 adjusted earnings per share (EPS) of at least $9.00. A reduction below that floor would contradict the earnings-stability premise. Form 8-K.
• The advance remains measurable. The supplied adjusted series shows a three-month price increase of 10.0% through 2026-09-09, with the close 2.3% below its $409.42 reference high. Continuation remains an inference bounded by the published $383 daily-close failure condition.

Bear Case

• Annual medical pressure remains unresolved. On 2026-07-29, Humana retained full-year insurance benefit-ratio guidance of 92.75%, plus or minus 25 basis points. An upward revision to that range would contradict the cost-control premise. Quarterly release.
• Quality recovery has a specific test. On 2026-07-29, management defined its top-quartile Stars objective as monthly Stars revenue per member 10% above the peer-group median. A disclosed result below that benchmark would miss management's stated objective; the share of members in highly rated plans alone cannot settle it. July earnings call.

Setup & Price Structure

The 2026-09-09 adjusted daily close was $400.02, against a $409.42 adjusted reference high in the same series. The research failure threshold remains $383, associated with the advance above the previously published 2026-08-31 adjusted close of $383.23. These are market reference levels.

The 14-period relative strength index (RSI) measured 68.2 on 2026-09-09. That momentum reading and the September analyst reiterations are observable; neither establishes crowded ownership. Moving-average distance, directional options exposure and investor-flow measurements are missing, so the evidence does not support a positioning verdict. The unchanged earnings outlook and unresolved quality-rating outcome support only modest confidence in continuation. September filing, analyst record.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Scheduled meeting window ends. The 2026-09-01 filing dates investor and analyst meetings through this day. It is a disclosed window endpoint, not a promised results release; silence would not establish improved performance. Form 8-K.
• ~2026-10-08, est. Final MA Star Ratings. Humana's 2026-09-01 filing confirms October publication by the Centers for Medicare and Medicaid Services (CMS), but no exact release day is confirmed. The estimated date concerns ratings affecting bonus year 2028; a CMS schedule placing publication elsewhere would invalidate the date estimate. Form 8-K.
• 2026-12-10 — Later margin-path checkpoint. Humana lists a virtual investor update on this date. Management's 2026-07-29 remarks identify it as the review of the 2028 commitments with bonus-year Stars visibility and preliminary membership expectations; withdrawal of the margin objective would break the operating thesis. Company calendar, July earnings call.

What Would Change Our Mind

Loss of the August advance would end the continuation case: a daily close below $383 breaches the research threshold associated with the 2026-08-31 adjusted close of $383.23. An adjusted daily close above the $409.42 reference high identified on 2026-09-09, occurring first, would complete the published price case; it would not prove the 2028 business objective.

The operating narrative would separately fail if Humana withdrew or lowered the at-least-3% pre-tax MA margin commitment reiterated on 2026-07-29. July earnings call.

Correlation Notes

FrontierPicks' Managed care & health services coverage record classifies the group as saturated on 2026-08-04, 2026-09-06 and 2026-09-10, alongside CNC, OSCR, AVAH and HNGE. That is an editorial assessment of the coverage cycle, not measured common ownership or return correlation. Paired return observations are missing, so no correlation coefficient or diversification claim is supported. Humana's company-specific continuation case remains bounded by the $383 daily-close condition despite the group's classification.